| Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca |
| Active, not recruiting | N/A | 287 | Europe | | AstraZeneca | Heart Failure | 12/23 | 12/23 | | |
| Completed | N/A | 239 | Europe | | AstraZeneca | Heart Failure | 03/24 | 03/24 | | |
| Active, not recruiting | N/A | 1221 | Japan | | AstraZeneca | Heart Failure | 12/24 | 12/24 | | |
EVOLUTION-HF, NCT05250011: Observation of Italian Patients With Heart Failure Being Treated With Dapagliflozin in Clinical Practice |
|
|
| Completed | N/A | 252 | Europe | Dapagliflozin, Forxiga | AstraZeneca, Fullcro s.r.l. | Heart Failure, Reduced Ejection Fraction | 04/24 | 04/24 | | |
| Recruiting | N/A | 1000 | Europe | | AstraZeneca | Heart Diseases, Cardiovascular Diseases, Heart Failure | 09/26 | 09/26 | | |
NCT05134701: Dapagliflozin Post Marketing Surveillance in HF and CKD |
|
|
| Active, not recruiting | N/A | 815 | RoW | | AstraZeneca | Heart Failure With Reduced Ejection Fraction, Chronic Kidney Disease | 10/24 | 10/24 | | |
NCT02969798: Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) |
|
|
| Recruiting | N/A | 700 | US | Dapagliflozin, farxiga, Saxagliptin, onglyza, Pioglitazone, actos, Metformin, glucophage | The University of Texas Health Science Center at San Antonio, American Diabetes Association, AstraZeneca, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG) | 12/24 | 07/25 | | |
NCT05970237: A Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension |
|
|
| Recruiting | N/A | 9000 | RoW | | Boryung Pharmaceutical Co., Ltd | Diabetes Mellitus, Hypertension | 12/24 | 12/24 | | |
NCT02695121: Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment |
|
|
| Recruiting | N/A | 1125000 | Europe, US | | AstraZeneca | Breast Cancer, Bladder Cancer | 12/24 | 12/24 | | |
| Active, not recruiting | N/A | 257 | Europe | | AstraZeneca | Heart Failure | 03/25 | 03/25 | | |
NCT05306210: Forxiga CKD Japan Post-Marketing Surveillance (PMS) |
|
|
| Active, not recruiting | N/A | 1029 | Japan | | AstraZeneca | Chronic Kidney Disease | 04/25 | 04/25 | | |